Slide 1: Letter to Pakistan Stock Exchange on Corporate Briefing Session
November 22, 2024 The General Manager Pakistan Stock Exchange Limited Stock Exchange Building, Stock Exchange Road, Karachi Subject: Corporate Briefing Session of Macter International Limited السالم عليكم Further to our letter dated November 18, 2024 on the above subject, please find attached here
Slide 2: Macter International Limited Corporate Briefing Session
Macter International Limited Corporate Briefing Session For the year ended June 2024 2023-24 November 25, 2024
Slide 3: Table of Content
Table of Mec Content Corporate Information 6 Challenges, Risks & Mitigants 2 About Us 7 Future Outlook 3 Pharmaceutical Market 4 Financial Highlights 5 Strong Product Pipeline
Slide 4: Corporate Information: Pattern of Shareholding, Credit Rating
Corporate Information Pattern of Shareholding Credit Rating VIS Credit Rating Company Ltd. (VIS) has upgraded our credit rating Maintained long-term rating of ‘A’ Upgraded short-term rating to ‘A-1’ from ‘A- 2’ Outlook on the assigned rating is ‘Stable’ Risk factors are small
Slide 5: Board of Directors
Board of Directors Macter Amanullah Kas: Chairman
Slide 6: About Us
About Us
Slide 7: Vision, Mission & Values
Vision, Mission & Values Vision Values We see Macter as an integrated global healthcare company serving patients, healthcare professionals and customers with high quality and innovative products and services. We are committed to achieve our vision in an ethical and socially responsible manner Missio
Slide 8: Our Core Business Areas
Our Core Business Areas @ Macter ee We provide comprehensive manufacturing We produce a wide range of services, ensuring quality and compliance pharmaceutical products that with global pharmaceutical manufacturing meet the highest standards of standards efficacy and safety sive Bus; yO" . “Mp ) uti
Slide 9: Our Journey
Our Journey 2021 Installed High Speed Tablet-in- Tablet technology 2024 2011 Member of IQIVA corporates having value Converted to Public Limited Company 10 Billion and above 2010 Completed Biological formulation and filling facilities, 2018 Obtained listing on PSX 2008 1. MOH approval for a dedicate
Slide 10: Robust Product Launch Journey
Robust Product Launch Journey
Slide 11: Our Global Presence
Our Global Presence Our Global Business Our reach extends beyond local markets, having a significant presence in over 15 countries across five global regions. Macter cis Cote Tajikistan — Kazakhstan Uzbekistan Azerbaijan Kyrgyzstan 6cc YIQy: “, lraq SOUTH EAST ASIA Philippines Myanmar Cambodia AFRIC
Slide 12: Manufacturing Facilities and Annual Production
Manufacturing Facilities Annual Production +50 Million Packs 2 Manufacturing Facilities >150 Products Active in 5 regions worldwide
Slide 13: Pakistan Pharma Market Overview
Pakistan Pharma Market Overview
Slide 14: Pakistan Pharma Market Evolution
Pakistan Pharma Market Evolution Pharma Industry Market Share Trend Pakistan Pharma Market Evolution PKR Billion
Slide 15: Industry Growth Dynamics
Industry Growth Dynamics @® {Pharma Mkt [National [J MNC 25.0% 22.6% 20.0% 15.0% 11.7% 11.3% 10.0% 10.8% 10.4% 5.0% 0.0% Source: IQVIA Q2 MAT 2024 2020 2021 2022 2023 2024
Slide 16: Macter's Standing: +10 Billion Club
Macter’s Standing: +10 Billion Club The highlighted Companies are the new entrants to the “10 Billion” club including Macter International Limited
Slide 17: Financial Highlights
Financial Highlights
Slide 18: Financial Highlights - For the year ended 2024
Financial Highlights - For the year ended 2024
Slide 19: Standalone Performance Highlights - 2024
Standalone Performance Highlights - 2024 Net turnover for the year ended 30th June 2024 was Rs. 7,535 Mn reflecting a 13% increase from last year. Our core prescription sales business grew by +23% vs last year on account of following; Sales • Strong performance of our brands such as Pegstim in Oncol
Slide 20: Net Sales & Profitability Trend
Net Sales & Profitability Trend Profit before tax Sales Net Profit to Turnover (%) PKR Million
Slide 21: Financial Highlights - Graphs
Financial Highlights - Graphs Gross Margin (%) Earning Per Share (PKR) 10 9 8 7 6 44.70 41.69 42.22 41.13 5 9.32 36.85 8.58 4 7.19 6.57 3 2 1 0.38 FY20 FY21 FY22 FY23 FY24 0 FY20 FY21 FY22 FY23 FY24 Return on Capital Employed (x) Current Ratio (x) 25 2 1.8 20 1.6 1.4 15 1.2 1 1.90 21.29 1.71 1.76 10
Slide 22: Key Brands
Key Brands -1000 RIAXONE) INIECTION 1000 MG Roa SPECTRUM CEmiALOSFORN Macter _ = nticort 2a ** Salmicort 5°" saimicort (Budesonide+Formatero Fumarate) meg *6™m0 eo "30 capsules: _ Sng Pegstim (Peg-filgrastim) ee | 6G} (Preservative Free} Macter
Slide 23: New Launches During 2023-2024
New Launches During 2023-2024
Slide 24: Strong Product Pipeline
Strong Product Pipeline
Slide 25: Successfully launched r-DNA Origin Seglutide
Strong Product Pipeline Successfully launched r-DNA Origin – Seglutide A Global Block Buster Biologic
Slide 26: First Company in Pakistan to Manufacture Heparin
Strong Product Pipeline First Company in Pakistan to Manufacture Heparin, a vital anticoagulant used globally reaffirming its leadership in bio-pharmaceutical innovation
Slide 27: Challenges, Risk & Mitigants
Challenges, Risk & Mitigants
Slide 28: Key Challenges, Risks & Mitigants
Key Challenges, Risks & Mitigants Key Challenges & Risks Mitigants Cost inflation and lag in compensatory Continuous focus on using green energy inflationary price adjustments in DRAP Devaluation of PKR Focus on export markets Global API and logistics Developing infrastructure to meet di
Slide 29: Future Outlook
Future Outlook
Slide 30: Future Outlook - Strategic Priorities
Future Outlook - Strategic Priorities
Slide 31: Thank You Q & A Session
® Macter Thank You Qa&A Session